Latest News
Conference Coverage
Guselkumab crushes skin disease in psoriatic arthritis patients
GENEVA – IL-23 inhibitor achieves consistent skin outcomes in psoriasis with and without arthritis.
Feature
After 6 weeks, HealthCare.gov activity still ahead of last year
As the end of this year’s open enrollment nears, however, plan selections are only about half of last year’s total.
News
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
It is the third biosimilar of Remicade to be approved by the FDA.
Feature
Award program to drive more community-based rheumatology research
The program offers financial and other support to encourage rheumatologists in day-to-day clinical practice to pursue cutting-edge research.
Conference Coverage
Sprifermin shows cartilage-building potential in knee OA patients
Interim results indicate that sprifermin could be the first investigational medicinal product to show a dose-dependent increase in cartilage...
News
FDA approves first therapy treatment for EGPA
Approval of using mepolizumab for EGPA was based on data from a 52-week clinical trial that compared it with placebo, according to the FDA.
From the Journals
Study supports methotrexate monotherapy with TNF inhibitor rescue for early RA treatment
Findings suggest that a stepwise treat-to-target strategy can prevent overtreatment in about one in four patients with early RA.
Feature
Early weight change has no special effect on mortality in RA
The so-called obesity paradox does not stand up to new evidence looking at the timing of weight change near the time of RA diagnosis.
Conference Coverage
Interleukin-23 inhibition for psoriasis shows ‘wow’ factor
Most patients with moderate to severe plaque psoriasis on either guselkumab or tildrakizumab have at least PASI 90 sustained response at 2 years...
Conference Coverage
Evidence builds for long-term ineffectiveness of steroid shots for knee OA
SAN DIEGO – Injections may actually boost the risk that condition will worsen
Conference Coverage
Virtual reality enters the rheumatology realm
SAN DIEGO – New feasibility study aims to understand its potential for pain.